BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34448437)

  • 1. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.
    Komrokji R; Melody M; Al Ali N; Chan O; Klimek V; Ball BJ; Sekeres MA; Lucas G; Maciejewski JP; Sallman DA; Padron E; Kuykendall A; Lasho T; Al-Kali A; Naqvi K; Steensma DP; Garcia-Manero G; Patnaik MM
    Leuk Lymphoma; 2022 Jan; 63(1):199-204. PubMed ID: 34448437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
    Mangaonkar AA; Lasho TL; Ketterling RP; Reichard KK; Gangat N; Al-Kali A; Begna KH; Pardanani A; Al Ali NH; Talati C; Sallman D; Padron E; Patnaik MM; Tefferi A; Komrokji R
    Blood Cancer J; 2022 Feb; 12(2):26. PubMed ID: 35105856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
    Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
    Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
    Patnaik MM; Tefferi A
    Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
    Nicolosi M; Mudireddy M; Vallapureddy R; Gangat N; Tefferi A; Patnaik MM
    Am J Hematol; 2018 Jan; 93(1):E27-E30. PubMed ID: 29067707
    [No Abstract]   [Full Text] [Related]  

  • 6. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
    Li P; Shahmarvand N; Lynch D; Gotlib JR; Merker JD; Zehnder JL; George TI; Ohgami RS
    Int J Lab Hematol; 2019 Jun; 41(3):345-352. PubMed ID: 30811101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.
    Aoyama Y; Sakai K; Kodaka T; Tsunemine H; Nishio K; Itoh T; Inoue D; Takahashi T
    J Clin Exp Hematop; 2019 Mar; 59(1):29-33. PubMed ID: 30726782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
    Long B; Shi H; Zhu C
    Hematology; 2020 Dec; 25(1):283-285. PubMed ID: 32657243
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
    Edahiro Y; Ochiai T; Hashimoto Y; Morishita S; Shirane S; Inano T; Furuya C; Koike M; Noguchi M; Usuki K; Shiratsuchi M; Nakajima K; Ohtsuka E; Tanaka H; Kawata E; Nakamae M; Ueda Y; Aota Y; Sugita Y; Ohara S; Yamasaki S; Asagoe K; Yoshida S; Yamanouchi J; Suzuki S; Kondo T; Kanisawa Y; Toyama K; Omura H; Mizuchi D; Sakamaki S; Ando M; Komatsu N
    Int J Hematol; 2023 Jul; 118(1):47-53. PubMed ID: 37058247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
    Patnaik MM; Tefferi A
    Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis with Cooccurrent SF3B1 and MPL Gene Mutations: A Case Report and Brief Review of the Literature.
    Park CH; Yun JW; Kim HY; Lee KO; Kim SH; Kim HJ
    Lab Med; 2020 May; 51(3):315-319. PubMed ID: 31858134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis.
    Lee MY; Jang S; Park CJ; Cho YU
    Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
    Montalban-Bravo G; Kanagal-Shamanna R; Darbaniyan F; Siddiqui MT; Sasaki K; Wei Y; Yang H; Chien KS; Naqvi K; Jabbour E; Kadia TM; Daver N; DiNardo C; Ravandi F; Pemmaraju N; Bose P; Verstovsek S; Pierce S; Bueso-Ramos C; Patel K; Do KA; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2021 Jul; 96(7):E246-E249. PubMed ID: 33811786
    [No Abstract]   [Full Text] [Related]  

  • 15. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
    Patnaik MM; Tefferi A
    Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
    Yoshimi A; Abdel-Wahab O
    Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
    Antelo G; Mangaonkar AA; Coltro G; Buradkar A; Lasho TL; Finke C; Carr R; Binder M; Gangat N; Al-Kali A; Elliott MA; King RL; Howard M; Melody ME; Hogan W; Litzow MR; Tefferi A; Fernandez-Zapico ME; Komrokji R; Patnaik MM
    Br J Haematol; 2020 May; 189(3):e104-e108. PubMed ID: 32128785
    [No Abstract]   [Full Text] [Related]  

  • 18. MDS/MPN-RS-T justified inclusion as a unique disease entity?
    Montalban-Bravo G; Garcia-Manero G
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101147. PubMed ID: 32460979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.
    Ok CY; Trowell KT; Parker KG; Moser K; Weinberg OK; Rogers HJ; Reichard KK; George TI; Hsi ED; Bueso-Ramos CE; Tam W; Orazi A; Bagg A; Arber DA; Hasserjian RP; Wang SA
    Mod Pathol; 2021 Jan; 34(1):20-31. PubMed ID: 32694616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
    Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
    Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.